Kyntra Bio (KYNB) Non-Current Deffered Revenue (2014 - 2026)

Kyntra Bio has reported Non-Current Deffered Revenue for 13 years, with the latest figure at $4.1 million in Q1 2026.

• Quarterly Non-Current Deffered Revenue fell 96.47% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (down 96.47% YoY) and the FY2025 annual result came in at $255000.0, down 99.78% from the prior year.
• Non-Current Deffered Revenue climbed to $4.1 million in Q1 2026 per KYNB's latest filing, from $255000.0 in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $205.4 million in Q2 2022 and troughed at $255000.0 in Q4 2025.
• A 5-year average of $128.1 million and a median of $147.1 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2022 and 2025: Non-Current Deffered Revenue surged 34.33% in 2022, then plunged 99.78% in 2025.
• Over 5 years, Non-Current Deffered Revenue stood at $185.7 million in 2022, then decreased by 15.17% to $157.6 million in 2023, then dropped by 27.19% to $114.7 million in 2024, then slumped by 99.78% to $255000.0 in 2025, then soared by 1498.04% to $4.1 million in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $4.1 million, $255000.0, and $573000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.